IMPROVED

IMPROvED: IMproved Pregnancy Outcomes by Early Detection; personalized medicine for pregnant women: novel metabolomic and proteomic biomarkers to detect pre-eclampsia and improve outcome

Coordinatore	UNIVERSITY COLLEGE CORK, NATIONAL UNIVERSITY OF IRELAND, CORK    more  Organization address address: Western Road city: CORK postcode: - contact info Titolo: Dr. Nome: David Cognome: O'connell Email: send email Telefono: 353214000000
Nazionalità Coordinatore	Ireland [IE]
Totale costo	7˙774˙977 €
EC contributo	5˙995˙390 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2012-INNOVATION-1
Funding Scheme	CP-FP
Anno di inizio	2012
Periodo (anno-mese-giorno)	2012-11-01   -   2016-10-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	UNIVERSITY COLLEGE CORK, NATIONAL UNIVERSITY OF IRELAND, CORK  Organization address address: Western Road city: CORK postcode: - contact info Titolo: Dr. Nome: David Cognome: O'connell Email: send email Telefono: 353214000000	IE (CORK)	coordinator	1˙113˙969.00
2	PRONOTA NV  Organization address address: TECHNOLOGIEPARK 4 city: GENT postcode: 9052 contact info Titolo: Dr. Nome: Vicky Cognome: Aerts Email: send email Telefono: +32 9 2411164 Fax: +32 9 2411169	BE (GENT)	participant	932˙100.00
3	METABOLOMIC DIAGNOSTICS LIMITED  Organization address address: WESTERN ROAD SUITE 2 28 city: CORK contact info Titolo: Mr. Nome: Charles Cognome: Garvey Email: send email Telefono: +353 86 3888803	IE (CORK)	participant	857˙800.00
4	UNIVERSITY OF KEELE  Organization address address: KEELE UNIVERSITY FINANCE DPT city: KEELE postcode: ST5 5BG contact info Titolo: Mr. Nome: James Cognome: Allman Email: send email Telefono: +44 1782 734389	UK (KEELE)	participant	667˙700.00
5	ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM  Organization address address: 's Gravendijkwal 230 city: ROTTERDAM postcode: 3015CE contact info Titolo: Mr. Nome: Jip Cognome: Chong Email: send email Telefono: +31 10 7037450 Fax: +31 10 7036801	NL (ROTTERDAM)	participant	653˙600.00
6	KAROLINSKA INSTITUTET  Organization address address: Nobels Vag 5 city: STOCKHOLM postcode: 17177 contact info Titolo: Dr. Nome: Miles Cognome: Davies Email: send email Telefono: +46 8 52486593 Fax: +46 8 310343	SE (STOCKHOLM)	participant	487˙022.00
7	REGION HOVEDSTADEN  Organization address address: KONGENS VAENGE 2 city: HILLEROD postcode: 3400 contact info Titolo: Dr. Nome: Maria Cognome: Skoog Email: send email Telefono: +45 3545 7165	DK (HILLEROD)	participant	307˙000.00
8	THE UNIVERSITY OF LIVERPOOL  Organization address address: Brownlow Hill, Foundation Building 765 city: LIVERPOOL postcode: L69 7ZX contact info Titolo: Ms. Nome: Jenny Cognome: Lawson Email: send email Telefono: +44 151 795 0314 Fax: +44 151 794 8728	UK (LIVERPOOL)	participant	274˙799.00
9	KLINIKUM DER UNIVERSITAET ZU KOELN  Organization address address: Kerpener Strasse 62 city: KOELN postcode: 50937 contact info Titolo: Mrs. Nome: Jutta Cognome: Landvogt Email: send email Telefono: +49 221 4785204 Fax: +49 221 47887752	DE (KOELN)	participant	246˙400.00
10	ACCELOPMENT AG  Organization address address: SEEFELDSTRASSE 198 city: ZUERICH postcode: 8008 contact info Titolo: Dr. Nome: Jeanette Cognome: Müller Email: send email Telefono: +41 44 4556600 Fax: +41 44 4556609	CH (ZUERICH)	participant	244˙200.00
11	MEDSCINET AB  Organization address address: Luntmakargatan 71 city: Stockholm postcode: 11351 contact info Titolo: Mr. Nome: Sten Cognome: Marthinsson Email: send email Telefono: +46 70 5729544	SE (Stockholm)	participant	132˙400.00
12	RIJKSUNIVERSITEIT GRONINGEN  Organization address address: Broerstraat 5 city: GRONINGEN postcode: 9712CP contact info Titolo: Mr. Nome: Dick Cognome: Veldhuis Email: send email Telefono: +31 50 3634142 Fax: +31 50 3634500	NL (GRONINGEN)	participant	78˙400.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'1 in 20 first time pregnancies are complicated by pre-eclampsia, the leading cause of maternal death in Europe. No clinically useful screening test exists; consequently, clinicians are unable to offer targeted surveillance or known/emerging preventative strategies. Consortium members have pioneered a personalised medicine approach to identifying blood-borne biomarkers through recent technological advancements, especially in the field of mass spectrometry and the comprehensive mapping of the blood metabolome and proteome. The overall objective of the IMPROvED project is to develop a sensitive, specific, high-throughput and economically viable early pregnancy screening test for pre-eclampsia. This will involve a multicentre, phase IIa clinical study to assess and refine novel and innovative prototype tests based on emerging metabolomic and proteomic technologies developed by SMEs within the consortium. The study will i) recruit 5000 first time pregnant women; ii) establish a high calibre biobank, augmented by accurate clinical metadata; iii) determine whether prototype predictive assays and algorithms translate to the clinical environment; iv) assess potential synergy of a combined metabolomic and proteomic approach and v) progress regulatory approval and development of the selected test into the clinical arena. The application of new technologies to identify ‘at risk’ patients in early pregnancy will allow stratified care with personalized fetal and maternal surveillance, early diagnosis and timely intervention. If an effective test halved antenatal visits and administration of therapies (such as aspirin) to those at risk reduced the incidence of disease by only 20%, potential savings would approximate to €4 billion of the estimated €9 billion/yr spent in Europe providing antenatal care for nulliparous women and treatment for pre-eclampsia. Moreover, an accurate predictive test would be a crucial step in reducing the life-threatening complications of the disease.'